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B-cell chronic lymphocytic leukemia is
associated with immune suppression and
an altered T-cell repertoire with expan-
sion of memory cells. Cytomegalovirus
(CMV) is a common herpes virus that
elicits a strong virus-specific T-cell im-
mune response after infection. We stud-
ied the CMV-specific CD4 T-cell re-
sponse in 45 patients and 35 control
subjects and demonstrated that it was
markedly expanded in the patient group,
averaging 11% of the CD4 pool com-
pared with 4.7% in controls. The magni-
tude of the CMV-specific CD4 immune
response increased with disease stage
and was particularly high in patients who
received chemotherapy. Within this group,
the CMV-specific response comprised
over 46% of the CD4 T-cell repertoire in
some patients. Serial analysis revealed
that CMV-specific immunity increased
during treatment with chemotherapy and
remained stable thereafter. CMV-seroposi-
tive patients exhibited a markedly altered
CD4T-cell repertoire with increased num-
bers of CD45R0 T cells and a reduction
in CD27, CD28, and CCR7 expression.
Overall survival was reduced by nearly 4
years in CMV-seropositive patients, al-
though this did not reach statistical sig-
nificance. CLL patients therefore demon-
strate an expansion of the CD4 CMV-
specific immune response, which is likely
to contribute to the immunological and
clinical features of this disease. (Blood.
2010;116(16):2968-2974)
Introduction
Infectious disease is a major cause of morbidity and mortality in
patients with B-cell chronic lymphocytic leukemia (B-CLL).1
Hypogammaglobulinemia and impaired function of the cellular
immune response can occur early in the course of disease and
contribute to the state of immune suppression.2-4 In addition,
treatments used to control the disease can themselves render
patients susceptible to infection.5 Many studies of T-cell phenotype
and function have been undertaken in patients with B-CLL and
have shown abnormalities in the phenotype of CD4 and CD8 T
cells, including inversion of the normal CD4:8 ratio6,7 and the
accumulation of terminally differentiated effector T cells with
relative absence of naive precursors.8,9 It has been suggested that
these abnormalities contribute to the immunosuppression of B-
CLL and indicate the presence of a tumor-specific CD4 T-cell
response.
Cytomegalovirus (CMV) is a human herpes virus that infects
the majority of the human population during their lifetime.
Infection is associated with the development of a vigorous CMV-
specific immune response, which typically comprises over 2% of
the CD8 T-cell repertoire.10 In states of immunosuppression, such
as following allogeneic transplantation or during HIV infection,
this value is often increased and is felt to represent cellular
response to subclinical viral reactivation occurring during immuno-
suppression.11 It has been shown that the CMV-specific CD8
T-cell response is similarly increased in patients with B-CLL and
the phenotype of CMV-specific cells was that of late differentiated
effector cells.12 Much less is known about the activity of the CD4
CMV-specific T-cell response in either healthy donors or in patient
groups. The development of intracellular staining for cytokine
production has led to the opportunity to study CMV-specific CD4
T-cell immunity in more detail.
CMV seropositivity is associated with the accumulation of
memory T cells and has been shown as a confounding factor in the
analysis of T-cell phenotype in patients with rheumatoid arthritis
and in normal ageing.13-15 Here, we have analyzed CD4 CMV-
specific T-cell responses in patients with B-CLL and have com-
pared these to an age-matched control group. We found that the
CMV-specific CD4 T-cell response is markedly increased in
patients with B-CLL and show that this is associated with
chemotherapy. These changes are so marked as to determine the
total CD4 T-cell repertoire of the patient.
Methods
Patient population
Seventy-three patients with B-CLL were recruited from the University
Hospitals NHS Trust, Birmingham, United Kingdom. Ethical permission
was obtained from the South Birmingham Ethics Committee and written
informed consent was provided in all cases in accordance with the
Declaration of Helsinki. Patients were studied at all stages of disease. A
control group of 49 healthy donors was recruited from a local cohort of
volunteers with a median age of 66 years (range 62–81), of which 35 donors
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were CMV seropositive. CMV seropositivity was determined by serologi-
cal testing and 45 patients were found to be CMV seropositive (Table 1).
There were no differences between the CMV-seropositive and seronegative
groups with respect to age, stage of disease, or treatment history. Ten
milliliters of blood was obtained at each time point and analysis used either
whole blood samples or peripheral blood mononuclear cells (PBMC)
obtained by density centrifugation and maintained in RPMI (GIBCO) with
10% fetal calf serum (FCS; GIBCO). The absolute lymphocyte count of
each sample was measured by automated cell analysis on a Coulter counter.
Measurement of absolute CD3, CD4, and CD8 T-cell counts
Absolute T-cell counts were determined by use of FACS analysis in
combination with the combined lymphocyte and monocyte counts obtained
from full blood count analysis. The antibodies anti-CD3–FITC, anti-CD4–
PE, and anti-CD8–Tricolor were used to stain whole blood samples and
the percentage of each population was determined by FACS analysis.
This percentage was then used to determine the absolute number of each
T-cell subset.
Detection of CMV-specific CD4 T cells
CMV-specific CD4 T cells were determined according to the previously
described method.16 Briefly, whole blood in sodium heparin was aliquoted
into 15-mL propylene tubes and the costimulatory monoclonal antibodies
anti-CD28 and anti-CD49d were added to the samples at a 1 g/mL final
concentration. CMV lysate or staphyloccocal enterotoxin B (positive
control) was added to the tubes and a negative control without antigen was
used in all cases. Tubes were incubated at 37°C for 6 hours, and in the
presence of 10 g/mL of the cytokine secretion inhibitor brefeldin A for
the final 4 hours. EDTA was added at final concentration of 2mM for
15 minutes at room temperature, and then the red blood cells were lysed and
the leukocytes were fixed by incubation of cultures with FACS lysing
solution (Becton Dickinson) for 10 minutes. Cells were washed in PBS
containing 0.5% bovine serum albumin (BSA) and 0.1% sodium azide, and
then permeabilized by incubation in FACS permeabilization buffer (Becton
Dickinson) for 10 minutes at room temperature. The cells then were washed
in PBS with BSA and sodium azide prior to staining.
Immunofluorescent staining and flow cytometric analysis
The following monoclonal antibodies were used in this study: anti-IFN
(FITC, PE); anti–IL-2 (FITC, PE); anti-TNF (FITC, PE); mouse IgG2a
(FITC, PE); mouse IgG1 (FITC, PE); CD49d (pure); and CD28 (pure); all
antibodies were obtained from Becton Dickinson Immunocytometry Sys-
tems. CD4 (ECD, PC5); CD8 (FITC); CD3 (PE); CD69 (PC5); CD57
(FITC, PE); CD28 (FITC); CD45RO (FITC, PE); CD45RA (FITC); CD27
(FITC); CD38 (FITC); and HLA-DR (FITC) antibodies and mouse IgG1
(ECD, TC) were obtained from Coulter Immunology. CD28 (TC) and CD8
(TC) antibodies were from Caltag. CCR7 (FITC) antibody was obtained
from R&D Systems. Cells were incubated with directly conjugated
monoclonal antibodies for 30 minutes in room temperature in the dark.
After staining, cells were washed, fixed in 1% paraformaldehyde in PBS
and then kept at 4°C until flow cytometric analysis. Four-color flow
cytometric analysis was performed on a flow cytometer. Between 2 104
to 5  104 CD4 cells were typically collected. Cells were gated on SSC
versus FSC to collect lymphocytes and then on CD4 cells versus SSC.
Data were analyzed using WinMDI software and displayed as dot plots of
cytokine versus CD69 fluorescence.
Materials
CMV Ag, strain AD169, was purchased from Microbix Biosystems Inc.
staphyloccocal enterotoxin B and Brefeldin A were purchased from Sigma;
and FACS lysing and Permeabilization solution from Becton Dickinson.
Statistical analysis
Kaplan-Meier analysis was used to determine the influence of CMV
seropositivity on survival in patients with B-CLL. A log-rank test was used
to test the difference between the 2 survival curves.
Results
T-cell count is increased in patients with B-CLL, and
CMV-seropositive patients exhibit an increment in CD3 and
CD8 T-cell counts
The number of CD3, CD3CD4 and CD3CD8 lymphocytes was
initially determined in peripheral blood from patients with B-CLL and
an age-matched control group. The CD3T-cell count was increased by
over 2 fold in B-CLL patients compared with controls (Table 2).
Furthermore, CMV seropositivity was associated with an increased
CD3 cell count in both the patients (CMV seropositive 2648/mL
(175-9936) vs CMV seronegative 2225/mL (113-8996, P .042) and
the control group (CMV seropositive 1100/mL (290-2670) vs CMV
seronegative 792/mL, (192-976) P .02).
The CD4 T-cell count was also increased in B-CLL patients in
comparison to the control group but was not influenced by CMV
serostatus. Indeed, the CD4 T-cell count was marginally de-
creased in CMV-seropositive individuals in both the patient
Table 1. Clinical characteristics of the patients studied
Parameter
CMV
seropositive
patients
CMV
seronegative
patients
No. of patients 45 (61.6%) 28 (38.4%)
Median age, y (range) 74.6 (52-87) 71.8 (56-89)
Sex
Male 26 (53.7) 17 (60.8%)
Female 19 (46.3) 11 (39.2%)
Stage of disease
Binet A 29 (64.4%) 18 (64.7%)
Binet B C 16 (35.6%) 10 (35.3%)
Treatment
No history of therapy 30 (66.6%) 19 (70.3%)
Positive history 15 (33.3%) 8 (29.7%)
Complications (during study period)
Autoimmune phenomena 2 3
Zoster reactivation 2 NF
Pneumonia 1 NF
Shingles 1 NF
Guillain-Barre syndrome 1 NF
Other cancers 4 NF
CMV indicates cytomegalovirus; and NF, not found.
Table 2. Absolute T-cell count in B-CLL patients and control group
T-cell subpopulations
(no/L)
B-CLL patients Age-matched controls
CMV seropositive CMV seronegative P CMV seropositive CMV seronegative P
CD3 2648 (175-9936) 2225 (113-8996) .042 1100 (290-2670) 792 (192-976) .02
CD4 1139 (123-4072) 1262 (57-5183) .14 467 (153-981) 566 (185-780) .10
CD8 1457 (151-7573) 1072 (49-6377) .019 541 (117-1043) 175 (122-656) .0007
B-CLL indicates ; and CMV, cytomegalovirus.
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(1139/mL vs 1262/mL) and control groups (467/mL vs 566/mL)
but this did not reach statistical significance.
CMV seropositivity had a particularly marked effect on the
CD8 T-cell count in both the patient and control groups. Within
the patient group, the mean CD8 T-cell count in CMV-
seropositive donors was 1460/mL compared with 1070/mL in the
CMV-seronegative group (P  .019). In the control group, the
corresponding values were 541/mL and 175/mL, respectively
(P  .001), and this observation likely reflects the reported in-
crease in the number of CMV-specific CD8 T cells that has been
observed in CLL patients.12
Of interest, patients with B-CLL exhibited increased T-cell
counts compared with the control group, irrespective of CMV
serostatus. The reasons for this are unknown but could reflect an
increased immune component against other infectious agents or a
potential tumor-specific immune response.
The number of CMV-specific CD4 T cells is increased in
patients with B-CLL
Blood samples were obtained from CMV-seropositive B-CLL
patients and age-matched controls and the number of CMV-specific
CD4 T cells was determined by cytokine flow cytometry (CFC).
CMV lysate was used as a source of antigenic stimulation prior to
analysis of IFN, TNF, or IL-2 expression within the CD3CD4
T-cell subset (Figure 1).
The CMV-specific CD4 T-cell response was expressed as a
percentage of the total CD4 T-cell repertoire and was found to be
significantly increased in B-CLL patients (Figure 1). This was the
case when CFC was determined by expression of either IFN,
TNF, or IL-2 (mean frequency 11% compared with 4.3% for
IFN; 11% vs 4.6% for TNF; and 3.6% vs 1.3% for IL-2). A lower
frequency IL-2 response to CMV stimulation was seen in both the
patient and control groups. The absolute number of CMV-specific
CD4 T cells was more markedly increased (3.5 fold) in CLL
patients compared with the control group (83 900/mL vs 24 100/
mL for IFN, 79 300/mL vs 26 900/mL for TNF; and 23 200/mL
vs 7850/mL for IL-2).
CMV-specific CD4 T cells are most markedly increased in CLL
patients with advanced stages of disease
In order to determine the parameters that might influence the
increase in CMV-specific CD4 T cells in B-CLL patients, the
frequency of CMV-specific CD4 T cells was compared in patients
with different stages of disease. A significant increase in the
frequency of CMV-specific CD4 T cells was seen in patients at
Binet stages B and C compared with patients at stage A of the
disease (Figure 2). The mean value in patients with advanced
disease was 15.2% (range 1.7%–43%) of the CD4 pool compared
with 8.2% (1.4%–34%) in patients at stage A disease (P  .03).
An increase in CMV-specific CD4 T cells is associated with
treatment for CLL
The increased CMV-specific CD4 T-cell response that was
observed in patients with advanced disease might reflect a response
to treatment, so patients were subdivided according to whether or
not they had been treated for their disease. A significant increase in
the CMV-specific CD4 T-cell response was observed in associa-
tion with a history of treatment (Figure 3A,B). The mean percent-
age of CMV-specific CD4 T cells was 17%, 16%, and 5.8% for
IFN, TNF, and IL-2 CFC, respectively, in patients with a history
of treatment compared with 8.06%, 7.08%, and 1.41% in untreated
patients (P  .017, P  .015, and P  .019, respectively). As
treatment can be associated with a decrease in the lymphocyte
count, it was felt to be important to identify the absolute CMV-
specific T-cell count in these groups. Despite the potentially
immune suppressive effects of chemotherapy, the mean number of
CMV-specific CD4 T cells was increased in treated patients at
138 000/mL, 116 000/mL, and 39 200/mL for IFN, TNF, and
IL-2 responses, respectively, compared with 55 900/mL, 42 400/
mL, and 6270/mL in untreated patients (P  .047, P  .045, and
P  .015 respectively).
These data raised the possibility that the increment in the
CMV-specific CD4 T-cell response was influenced solely by
treatment for CLL rather than the underlying disease itself.
However, a comparison between the untreated patient group and
controls revealed a significant increase in both the frequency and
number of CMV-specific CD4 T cells between untreated patients
and the control group (mean 8.06% vs 4.3% of CD4 T cells,
Figure 1. Higher frequencies of CMV-specific CD4 T cells are present in
patients with B-CLL. CMV-specific CD4 responses were assessed using CFC
following stimulation of whole blood using CMV lysate. CMV-specific T cells were
determined by production of intracellular (A) IFN, (B) TNF, or (C) IL-2. A higher
frequency and absolute number of CMV-specific CD4 T cells were present in
CMV-seropositive patients relative to the age-matched CMV-seropositive control
group (n  35).
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P  .03 and 55 900/mL compared with 24 100/mL, P  .04;
Figure 3C).
The CMV-specific CD4 T-cell immune response increases
during episodes of treatment with chemotherapy
In order to understand the observation of an increased CMV-
specific immune response in patients who had undergone treat-
ment, we elected to perform serial analysis of the immune response
during treatment episodes. Two patients receiving monthly courses
of fludarabine (40 mg/m2 orally for 5 days), as well as 1 patient
receiving chlorambucil at a dose of 4 mg daily, were studied at
monthly intervals.
The magnitude of the CMV-specific immune response, ex-
pressed either as a percentage of the CD4 T-cell pool or as an
absolute number of cells, increased markedly during treatment with
chemotherapy, peaking at approximately 4 months following
fludarabine treatment compared with a slower rise in those
receiving chlorambucil (Figure 4A). In contrast, serial analysis of
several patients who received chemotherapy more than 1 year ago
showed stable or slowly falling numbers of CMV-specific T cells
(Figure 4B). Patients who had not been treated also demonstrated
stable T-cell numbers.
The expanded CMV-specific CD4 T-cell pool determines the
CD4 T-cell repertoire in CMV-seropositive B-CLL patients
CMV-specific CD4 populations exhibit a characteristic effector
memory phenotype with a pattern of CD45ROCD27CD28
CD57 expression.14,15 This profile was also seen in the analysis of
CMV-specific responses in the CLL patient cohort (data not
shown). Several abnormalities of the CD4 T-cell repertoire have
been reported in B-CLL patients6,9 and it was felt to be important to
determine if CMV infection contributed to these features. CD28
and CD57 T cells have previously been correlated with specific
clinical features in CLL, such as neutropenia and clonal T-cell
expansions. Use of multicolor cytometry allowed the study of
coexpression of CD28 with CD57. We observed that 9.5% of CD4
T cells showed a CD28CD57 phenotype in CMV-seropositive
patients compared with 1% in the uninfected group (Figure 5A;
P  .00002).
The CD4 T-cell repertoire in healthy CMV-seropositive el-
derly donors shows a unique profile in relation to uninfected
individuals,14 and we therefore went on to compare the CD4 pool
in CMV-seropositive subjects in both the CLL patient and control
groups. CLL patients showed an altered pattern of expression of all
phenotypic markers on the total CD4 T-cell repertoire when
compared with the control group (Figure 5B). In particular, there
was reduced expression of the important costimulatory and sur-
vival molecules CD27 and CD28, as well as CD45RA and CCR7,
which are observed on naive and/or central memory cells, respec-
tively. In contrast, the expression of CD57 and CD45RO, both of
which are expressed on late differentiated effector memory cells,
was increased in CMV-seropositive patients. These findings show
that although CMV modulates the CD4 T-cell repertoire in
healthy donors, these effects are much more marked in the CLL
patient group, which reflects the great increase in the absolute
CMV-specific CD4 T-cell count.
More infectious episodes were seen in the CMV-seropositive
cohort but CMV seropositivity had no effect on overall patient
survival
Comparison of the clinical features of the CLL cohort in relation to
CMV serostatus showed that major infectious episodes were more
commonly observed within the CMV-seropositive cohort (Table 2).
Clinical data were therefore obtained on the entire cohort in order
to see if CMV seropositivity had any influence on patient survival.
0
1 0
2 0
3 0
4 0
5 0 P = .0 3
Figure 2. The frequency of CMV-specific CD4T cells in B-CLL patients is increased
in advanced disease. The frequency of CMV-specific CD4 T cells was determined by
IFN production and grouped according to the Binet stage of disease. CMV-specific CD4
T cells represented 8.2% of the CD4 T-cell pool in patients with stage A disease (n 29)
compared with 15.2% in patients at Binet stages B and C (n 16).
Figure 3. The frequency of CMV-specific CD4 T cells is increased in patients
with a history of treatment. CMV-specific CD4 T cells were measured in
CMV-seropositive patients and expressed (A) as a percentage of the CD4 T-cell
pool or (B) as an absolute number. The mean percentage of CMV-specific CD4
T cells was 17%, 16%, and 5.8% for IFN, TNF, and IL-2 responses, respectively, in
patients with a history of treatment compared with 8.06%, 7.08%, and 1.41%,
respectively, in untreated patients (P  .017, P  .015, and P  .019). The mean
number of CMV-specific CD4 T cells in CMV-seropositive treated patients was
138 300/mL, 115 800/mL, and 39 200/mL for IFN, TNF, and IL-2 responses,
respectively, compared with 55 900/mL, 42 400/mL, and 6270/mL in untreated
patients (P  .047, P  .045, and P  .015, respectively). (C) A significant difference
was observed in the frequency and number of IFN-positive CMV-specific CD4
T cells between untreated CMV-seropositive patients and the CMV-seropositive
control group (mean 8.06% of CD4 T cells compared with 4.3%, P  .03, and
55 900/mL compared with 24 100/mL, P  .04; n  35).
CMV-SPECIFIC CD4 T CELLS ARE INCREASED IN CLL 2971BLOOD, 21 OCTOBER 2010  VOLUME 116, NUMBER 16
For personal use only.on August 20, 2017. by guest  www.bloodjournal.orgFrom 
Information was available for 53 patients, of which 23 were dead
and 30 were still alive at the time of analysis. For patients still alive,
the median follow-up time was 105 months (range 6-212 months).
Reverse Kaplan-Meier analysis of all patients gave a median
follow-up time for all patients of 117 months.
Sixteen patients were CMV seronegative (5 dead; 11 censored)
and 37 were CMV seropositive (18 dead; 19 censored). No
differences were observed in the type of chemotherapy used in each
group. Those patients who were seronegative for CMV demon-
strated an increased survival compared with CMV-seropositive
patients, with a median survival estimated of 157 months compared
with 112 months. (Figure 6) However, although the hazard ratio
was 0.67 (95% CI: 0.25 to 1.81), indicating an observed 33%
reduction in the risk of death for CMV-seronegative patients, this
effect did not reach statistical significance due to the small cohort
size (P  .42).
Discussion
A wide range of abnormalities within the T lymphoid system have
been observed in patients with B-CLL. A characteristic feature is an
Figure 4. The proportion of CMV-specific CD4 T cells
increases markedly during treatment with chemo-
therapy. (A) The temporal kinetics of the CMV-specific
CD4 T-cell response was assessed in relation to treat-
ment history. The frequency and absolute number of
IFN-producing CD4 T cells increases sharply during
treatment with chlorambucil or fludarabine. (B) Examples
of the kinetics of the CMV-specific CD4 T-cell immune
response in 3 patients who were studied serially at
3 monthly intervals. Patient 1 showed a stable immune
response prior to commencing treatment with fludara-
bine, after which the CMV-specific CD4 T-cell response
peaked at 37.7% of the CD4 T-cell pool after 2 months
and then declined. Patient 2 received treatment with
chlorambucil and also exhibited an increase in the CMV-
specific CD 4 T-cell immune response, which increased
up to 5 months after treatment. Patient 3 was untreated
and showed a stable CMV-specific immune response.
FACS analysis was gated on CD4 T cells and IFN
expression is shown on the x-axis and CD69 on the
y-axis. The absolute CD4 T-cell counts (cells/L) were
(A) 671, 540, 530, and 642 at 0, 4, 8, and 12 months;
(B) 1104, 829, 800, and 983 at 0, 4, 8, and 14 months; and
(C) 389, 377, 417, and 97 at 6, 10, 12, and 16 months,
respectively.
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increase in the CD45RO memory T-cell population and a
comparable reduction in the CD45RA naive subset.17 Functional
abnormalities18 and clonal expansions of T cells have also been
observed,19 and it has been suggested that this may represent a
tumor-specific immune response, although no antigenic specificity
has been demonstrated. High numbers of cytotoxic T cells that
express perforin have also been reported in the CD4 compart-
ment20 and, importantly, changes in the T-cell repertoire are
associated with clinical complications. In particular, the develop-
ment of neutropenia has been specifically associated with increased
numbers of CD57 T lymphocytes.21
In this report, we characterized the CD4 T-cell response to
cytomegalovirus in patients with B-CLL and have made a number
of important observations. The most striking finding is that the
absolute magnitude of the CMV-specific CD4 T-cell response is
increased by over 3 fold in patients with B-CLL. Indeed, in
2 patients, the proportion of the CD4 T-cell pool directed against
this virus was measured at 44% and 46%, respectively, which are
among the highest values ever reported for the CMV-specific CD4
T-cell response. As some CMV-specific CD4 T cells may not have
the capacity to produce IFN, and so would not be detectable by
our cytokine assay, the true value may be even higher.
Having observed this effect, it became important to address the
potential factors that might be related to the expansion. Initially, we
looked at the effect of disease stage on the magnitude of CMV-
specific immunity, and revealed that the CD4 T-cell response
doubled as patients progressed from Binet stage A to stage C, and
patients with the greatest absolute levels of CMV-specific immu-
nity were almost always those with progressive disease. When
patients were subdivided on the basis of treatment history, the size
of the CMV-specific immune response was shown to be far greater
in patients who had undergone chemotherapy. Treatment with
either chlorambucil or fludarabine doubled the magnitude of the
CMV-specific cellular response. However, although treatment
further expands the CMV-specific immune repertoire, it should be
noted that the CD4 T-cell response is increased in all CLL
patients, irrespective of treatment history.
A prospective analysis of patients undergoing chemotherapy
allowed us to determine the kinetics of the CMV-specific immune
response. The CMV-specific CD4 T-cell immune response in-
creased by approximately 3 fold in patients during treatment with
fludarabine or chlorambucil. Interestingly, the rate of this increase
was dependent on the nature of the treatment, and the half-life of
T-cell expansion was measured at 40 days during fludarabine
treatment and 120 days during chlorambucil treatment.
The observation that the CMV-specific CD4 T-cell immune
response increased in patients with CLL is somewhat paradoxical
given the immune suppression that is associated with this disease.
However, the magnitude of the CMV-specific immune response is
strongly boosted by episodes of viral reactivation,22 and we suspect
that the immune suppression associated with CLL leads to subclini-
cal viremia, which in turn triggers an increase in the CMV-specific
immune response.
Strong evidence for this is seen in our prospective studies,
where the CMV-specific immune response increases markedly
within the first 3 months following immunosuppressive chemo-
therapy. Interestingly, we were not able to detect CMV reactivation
by PCR within this cohort, which indicates that viral replication is
Figure 5. CMV-seropositive patients have an altered CD4 T-cell
repertoire. (A) CD28CD57CD4T cells are present almost exclusively
in CMV-seropositive patients. PBMC were stained with monoclonal
antibodies against CD8, CD28, and CD57, and the relative expression of
CD28 and CD57 was determined on the CD8 T-cell populations of
CMV-seropositive and seronegative patients. Significant differences in
the number of CD57, CD28 and CD57CD28 populations were
observed between the 2 groups. (B) The phenotype of the CD4 T-cell
repertoire is markedly altered in CMV-seropositive patients (n  12)
compared with an age-matched CMV-seropositive control group (n  10).
PBMC were stained with monoclonal antibodies against CD4, CD27,
CD28, CD57, CD45RA, CD45RO, and CCR7, and the relative expression
of each marker was determined in the CD4 T-cell population. Significant
differences were observed between the 2 groups.
Figure 6. CMV-seronegative B-CLL patients show a trend toward increased
overall survival compared with the CMV-seropositive group. Kaplan-Meier
analysis was used to determine the influence of CMV seropositivity on survival in
patients with B-CLL. A log-rank test was used to test the difference between the
2 survival curves. The median survival of the CMV-seronegative group was estimated
at 157 months compared with 112 months for the CMV-seropositive patients
(P  .42)
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effectively controlled in CLL patients undergoing chemotherapy
with fludarabine or chlorambucil. However, it is to be expected that
more intensive chemotherapy would subvert the ability of the
immune response to respond to viremia, and this is likely to explain
the high rates of CMV reactivation that are observed after treatment
with alemtuzumab.23
CMV-specific CD4 T cells exhibit a characteristic phenotype
with high levels of expression of CD57 and CD45RO, but with
greatly reduced levels of CD28. When we compared the total CD4
T-cell pool in CLL patients to that of healthy donors, we observed
that CMV seropositivity markedly influenced the global T-cell
repertoire. This reinforces the understanding that chronic CMV
infection is one of the most profound modulators of the lymphoid
pool24 and should be taken into account in studies of immune
profile in relation to disease.
Features such as an increase in memory or CD57 T cells have
been associated with clinical complications of CLL, and it became
important for us to determine the influence of CMV seropositivity
on the clinical characteristics of the patients within this cohort.
Serious infections such as pneumonia and shingles were seen only
in the CMV-seropositive patients, and as the relative usage of
fludarabine was comparable in both groups, this might suggest that
CMV infection increases the degree of immune suppression within
patients. Survival data were only available on 53 patients, but
importantly, overall survival was reduced by nearly 4 years in the
CMV-seropositive group. This observation was not statistically
significant with this sample size but it demonstrates an urgent need
to study larger cohorts to determine the importance of CMV
serostatus on the clinical course of patients with CLL. There is
increasing interest in the potential contribution of CMV infection to
immune senescence, and the potential mechanisms by which CMV
carriage could impair immune function include reduction in the
naive T-cell pool or secretion of soluble immunomodulatory
mediators from the expanded memory population.
Chronic herpes virus infections are ubiquitous in all populations
and relatively little attention has been given to their potential to
modulate the natural history of human disease. Our studies suggest
that CMV infection has a profound influence on the immune
system in patients with B-CLL and that this effect increases with
disease progression. Further studies are required to understand the
clinical importance of this association and to investigate the
potential therapeutic opportunities that may be revealed.
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